Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
BUSINESS
NEC Harnessing AI Prowess to Pursue Global Players in Cancer Vaccine Race
Japanese electronics giant NEC is drawing on its unique artificial intelligence technology to develop cancer vaccines, chasing overseas players in the field such as Moderna with its pipeline targeting a wide range of solid tumors. “Theoretically, we can create a…
To read the full story
Related Article
- NEC Joins European AI Vaccine Project for Pandemic Preparedness
October 27, 2026
- NEC’s Neoantigen Therapy Shows Immunogenicity in Early TNBC Trial
October 26, 2026
- NEC Crafts Data Platform to Advance Personalized Cancer Vaccine Program
October 28, 2025
- NEC Touts AI as Core of Personalized Cancer Vaccine Development
September 1, 2025
- NEC Snaps Up Norway’s Bioinformatics Firm
July 30, 2019
- NEC Ties Up with French Biotech to Develop Neoantigen Vaccines Using AI
May 28, 2019
- NEC Ventures into AI-Based Drug Discovery Biz
December 21, 2016
BUSINESS
- Espha Taps Korean Eylea Follow-On for First Biosimilar Foray
November 4, 2026
- Kyowa Kirin Won’t Stop Drug Launches over MFN Pricing: CEO
November 4, 2026
- Takara Bio, S-RACMO Finalize Cell Processing CDMO Transfer for January
November 4, 2026
- Roche Launches CDx for Takeda’s Elahere in Japan
November 4, 2026
- Santen’s Myopia Drug Bags Approval in South Korea
November 4, 2026
Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…